Type 1 Diabetes Clinical Trial
— AstronautOfficial title:
Acute Effects of Sodium-glucose Cotransporter-2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes
Verified date | January 2021 |
Source | Steno Diabetes Center Copenhagen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background: Inhibiting the sodium-glucose cotransporter-2 (SGLT2) has been observed to reduce risk of cardiovascular events and kidney failure in type 2 diabetes. The exact mechanisms of the beneficial effects of SGLT2 inhibition (SGLT2i) are still unknown. Kidney hypoxia has been demonstrated in diabetic kidney disease and SGLT2i is thought to relieve hypoxia in the kidneys. Mitochondrial dysfunction and autonomic dysfunction might also contribute to kidney hypoxia. Objective: The primary aim of the study is to assess the acute effects of SGLT2 inhibition on parameters reflecting oxygenation and oxygen consumption of the human kidney in persons with type 1 diabetes. Exploratory aims are to investigate acute changes in oxygen availability and oxygen access to the kidneys after SGLT2i. This include measures of peripheral blood oxygenation, mitochondrial function and autonomic function. Methods: Acute intervention study with oral dapagliflozin given in two doses each of 50 mg or matching placebo as intervention. Kidney oxygenation and perfusion parameters will be assessed by blood-oxygen-dependant level magnetic resonance imaging. Mitochondrial function will be assessed by extracellular flux analysis on lymphocytes. Autonomic function will be assessed by measuring baroreflex sensitivity. Design: Randomized, double blinded, placebo-controlled, cross-over intervention study. Study population: Fifteen healthy controls are recruited by advertisement and 15 patients with type 1 diabetes recruited from Steno Diabetes Center Copenhagen. Endpoints: Primary end-point: Renal cortical and medullary oxygenation (T2*). Exploratory end-points: Renal cortical and medullary perfusion, renal artery flow, renal oxygen consumption, peripheral capillary oxygen saturation (SpO2), arterial oxygen partial pressure (PaO2), arterial oxygen saturation (SaO2), lymphocyte mitochondrial function, baroreflex sensitivity. Timeframe: Inclusion of patients from January 2020. Last patient last visit January 2021. Data analysis completed spring 2021, presentation autumn 2021 and publications Winter 2021.
Status | Completed |
Enrollment | 30 |
Est. completion date | January 1, 2021 |
Est. primary completion date | September 1, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion criteria healthy controls: - Written informed consent must be provided before participation - Male or female patients > 18 years of age - Capable of lying in a MR-scanner for two hours Inclusion criteria persons with type 1 diabetes: - Written informed consent must be provided before participation - Male or female patients >18 years of age with a diagnosis of type 1 diabetes (WHO criteria) - Urinary albumin creatinine ratio (UACR) =30 mg/g in 2 out of 3 consecutive samples (albuminuria) prior to randomization assessed from electronic laboratory database. - Capable of lying in a MR-scanner for two hours Exclusion criteria for all: - Non-diabetic kidney disease as indicated by medical history and/or laboratory findings - Renal failure (eGFR<15 ml/min/1.73m2), dialysis or kidney transplantation - Treatment with beta-blocking medication - Uncontrolled arrhythmia, 2. or 3. degree AV-block or sick sinus syndrome - assessed from a standard 12-lead electrocardiogram - Pregnancy or breastfeeding (urine HCG is performed on all fertile women) - Systolic blood pressure < 90 or > 200 mmHg - Patients who, in the judgement of the investigator, is incapable of participating - Exclusion criteria for MRI - Claustrophobia - Known heart disease - Known lung disease - Have had surgery the past six weeks - Have foreign bodies of metal in the body (e.g. pacemaker, metal plates, metal screws) - Exclusion criteria for arterial blood gas sampling (only patients with type 1 diabetes) - Absent pulse - Raynauds syndrome - Buergers Disease (thromboangiitis obliterans) - Inadequate or interrupted circulation - Anticoagulation treatment - Coagulopathies (hypo or hyper coagulable states) - Arterial atherosclerosis - Insufficient collateral perfusion - Partial or full thickness burns over the cannulation site - Synthetic arterial or vascular grafts or infection at the proposed site of cannulation Patients with type 1 diabetes will have the possibility to participate in the study without getting arterial blood gas sampling. |
Country | Name | City | State |
---|---|---|---|
Denmark | Steno Diabetes Center Copenhagen | Gentofte |
Lead Sponsor | Collaborator |
---|---|
Steno Diabetes Center Copenhagen | Glostrup University Hospital, Copenhagen, Novo Nordisk A/S |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Renal oxygenation | Blood Oxygen Level Dependent (BOLD) Magnetic Resonance Imaging (MRI) assessing the transverse relaxation time of atomic nuclei in the tissue (T2*) in miliseconds (ms). | From baseline to +3 hours from intervention | |
Primary | Change in Renal oxygenation | BOLD MRI assessing the transverse relaxation time of atomic nuclei in the tissue (T2*) in miliseconds (ms). | From baseline to +6 hours from intervention | |
Secondary | Change in renal cortical and medullary perfusion | Renal tissue perfusion can be measured noninvasively with MRI using arterial spin labelling (ASL). It is measured in mL/g/min. | From baseline to +3 hours from intervention | |
Secondary | Change in renal cortical and medullary perfusion | Renal tissue perfusion can be measured with MRI using arterial spin labelling (ASL). It is measured in mL/g/min. | From baseline to +6 hours from intervention | |
Secondary | Change in renal artery flow | Renal artery flow can be measured by using phase contrast (PC) MRI. It is measured in mL/min. | From baseline to +3 hours from intervention | |
Secondary | Change in renal artery flow | Renal artery flow can be measured by using phase contrast (PC) MRI. It is measured in mL/min. | From baseline to +6 hours from intervention | |
Secondary | Change in renal oxygen consumption | Renal oxygen consumption can be measured using Q-flow combined with BOLD MRI. It is measured in pmol/min/microgram protein. | From baseline to +3 hours from intervention | |
Secondary | Change in renal oxygen consumption | Renal oxygen consumption can be measured using Q-flow combined with BOLD MRI. pmol/min/microgram protein | From baseline to +6 hours from intervention | |
Secondary | Change in peripheral capillary oxygen saturation (SpO2) | Pulse oximetry on index finger of the right hand. Estimates blood oxygen saturation from capillary blood. Measured in %. | From baseline to +3 hours from intervention | |
Secondary | Change in peripheral capillary oxygen saturation (SpO2) | Pulse oximetry on index finger of the right hand. Estimates blood oxygen saturation from capillary blood. Measured in %. | From baseline to +6 hours from intervention | |
Secondary | Change in blood oxygen partial pressure (PaO2) | Blood gas analysis on arterial blood. Measured in kPa. | From baseline to +3 hours from intervention | |
Secondary | Change in blood oxygen partial pressure (PaO2) | Blood gas analysis on arterial blood. Measured in kPa. | From baseline to +6 hours from intervention | |
Secondary | Change in arterial blood oxygen saturation | Blood gas analysis on arterial blood. Measured in %. | From baseline to +3 hours from intervention | |
Secondary | Change in arterial blood oxygen saturation | Blood gas analysis on arterial blood. Measured in %. | From baseline to +6 hours from intervention | |
Secondary | Change in Peripheral Blood Monocyte mitochondrial function | Seahorse X96 analyzer. Analyzes the oxygen consumption rate (OCR), measured in pMoles/min. | From baseline to +12 hours from intervention | |
Secondary | Change in levels of circulating inflammatory markers | Commercially available panel from the company Olink. Includes 92 biomarkers. Information on the panel can be found here: https://www.olink.com/products/inflammation/#. | From baseline to +12 hours from intervention | |
Secondary | Change in baroreflex sensitivity | Calculated from continous blood pressure and the distance between the R-waves in a continuous ecg. Baroreflex sensitivity describes how much heart-rate changes when blood pressure changes. Assessment of baroreflex sensitivity is done in a measurement of 5 minutes. The unit is ms/mmHg. | From baseline to +12 hours from intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05653518 -
Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
|
N/A | |
Enrolling by invitation |
NCT05515939 -
Evaluating the InPen in Pediatric Type 1 Diabetes
|
||
Completed |
NCT05109520 -
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
|
||
Recruiting |
NCT04016987 -
Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT04190368 -
Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05413005 -
Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus
|
Early Phase 1 | |
Active, not recruiting |
NCT04668612 -
Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes
|
N/A | |
Completed |
NCT02837094 -
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
|
Phase 1 | |
Recruiting |
NCT05414409 -
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
|
Phase 2 | |
Recruiting |
NCT05670366 -
The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT05418699 -
Real-life Data From Diabetic Patients on Closed-loop Pumps
|
||
Completed |
NCT04084171 -
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
|
N/A | |
Recruiting |
NCT06144554 -
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
|
||
Recruiting |
NCT05153070 -
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
|
Phase 2 | |
Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
Completed |
NCT05281614 -
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
|
Early Phase 1 | |
Withdrawn |
NCT04259775 -
Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT01600924 -
Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
|
||
Completed |
NCT02914886 -
Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS)
|
Phase 4 | |
Completed |
NCT02897557 -
Insulet Artificial Pancreas Early Feasibility Study
|
N/A |